The mitochondrial amidoxime reducing component 1 (MTARC1), also known as MOSC2. is a molybdenum-containing enzyme encoded by the *MTARC1* gene. It belongs to the mARC enzyme family, which catalyzes the reduction of N-hydroxylated compounds, playing a role in detoxifying xenobiotics and endogenous metabolites. MTARC1 is anchored to the mitochondrial outer membrane and contains a molybdenum cofactor (MoCo)-binding domain critical for its enzymatic activity.
Research on MTARC1 has gained attention due to its involvement in lipid metabolism and association with metabolic disorders. Studies link MTARC1 dysfunction to non-alcoholic fatty liver disease (NAFLD), insulin resistance, and cardiovascular diseases. Its role in modulating hepatic steatosis and triglyceride levels highlights its potential as a therapeutic target.
MTARC1 antibodies are essential tools for detecting protein expression, localization, and post-translational modifications. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study MTARC1 in cell lines, animal models, and human tissues. Commercially available antibodies are typically validated for specificity using knockout controls. Recent studies also employ MTARC1 antibodies to explore its interaction partners and regulatory mechanisms in mitochondrial pathways.
Overall, MTARC1 antibodies facilitate mechanistic insights into its biological functions and disease relevance, bridging gaps between genetic associations and metabolic pathophysiology.